Prescription Medicine Leaders

Established prescription-drug franchises pair ongoing treatment demand with opportunities from new indications and pipeline renewal. With technology shares under pressure, this basket focuses on medicine sales rather than infrastructure spending, while Amgen's upcoming earnings provide a near-term execution check. Patent expirations, clinical setbacks and reimbursement pressure remain material risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, GILD, NVO Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.